Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids

被引:72
作者
Hesselink, DA
Ngyuen, H
Wabbijn, M
Gregoor, PJHS
Steyerberg, EW
van Riemsdijk, LC
Weimar, W
van Gelder, T
机构
[1] Erasmus Med Ctr, Dept Internal Med, Renal Transplant Unit, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus Med Ctr, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands
[3] Erasmus Med Ctr, Dept Pharm, Clin Pharmacol Unit, NL-3000 CA Rotterdam, Netherlands
关键词
corticosteroids; drug interactions; kidney transplantation; pharmacokinetics; tacrolimus;
D O I
10.1046/j.0306-5251.2003.01882.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To evaluate the effect of corticosteroids on tacrolimus pharmacokinetics. Methods In a randomized trial, kidney transplant recipients were treated with tacrolimus and mycophenolate mofetil with either daclizumab (n = 31) or 3 months of prednisone (n = 34). Tacrolimus dose-adjusted predose concentrations (C,,) at month 1-6 were compared between both groups and within the corticosteroid group before and after prednisone withdrawal. Results At month 1 the tacrolimus dose-adjusted C-o in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml(-1) mg(-1) kg(-1) in the daclizumab group. The tacrolimus dose-adjusted C-o within the corticosteroid group at month 1 and 2 was 42% and 29% lower compared with month 4 (P < 0.001). Conclusions A higher tacrolimus dose is required to reach target concentrations when used in combination with corticosteroids.
引用
收藏
页码:327 / 330
页数:4
相关论文
共 14 条
[1]   Renal allograft dysfunction associated with rifampin-tacrolimus interaction [J].
Chenhsu, RY ;
Loong, CC ;
Chou, MH ;
Lin, MF ;
Yang, WC .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (01) :27-31
[2]   Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes [J].
Christians, U ;
Schmidt, G ;
Bader, A ;
Lampen, A ;
Schottmann, R ;
Linck, A ;
Sewing, KF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (03) :187-190
[3]   Cyclosporin -: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®)1 in organ transplantation [J].
Dunn, CJ ;
Wagstaff, AJ ;
Perry, CM ;
Plosker, GL ;
Goa, KL .
DRUGS, 2001, 61 (13) :1957-2016
[4]   Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients [J].
Hesse, CJ ;
Baan, CC ;
Balk, AHMM ;
Metselaar, HJ ;
Weimar, W ;
van Gelder, T .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (07) :2988-2990
[5]  
Krähenbühl S, 1998, TRANSPLANTATION, V66, P1113
[6]   Clinical management of tacrolimus drug interactions in renal transplant patients [J].
Moreno, M ;
Latorre, A ;
Manzanares, C ;
Morales, E ;
Herrero, JC ;
Dominguez-Gil, B ;
Carreño, A ;
Cubas, A ;
Delgado, M ;
Andres, A ;
Morales, JM .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (06) :2252-2253
[7]   Therapeutic drug monitoring of cyclosporine and tacrolimus [J].
Oellerich, M ;
Armstrong, VW ;
Schütz, E ;
Shaw, LM .
CLINICAL BIOCHEMISTRY, 1998, 31 (05) :309-316
[8]  
Schrama YC, 1998, J HYPERTENS, V16, pS33
[9]   Nifedipine interaction with tacrolimus in liver transplant recipients [J].
Seifeldin, RA ;
MarcosAlvarez, A ;
Gordon, FD ;
Lewis, WD ;
Jenkins, RL .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) :571-575
[10]   Tacrolimus - An update of its pharmacology and clinical efficacy in the management of organ transplantation [J].
Spencer, CM ;
Goa, KL ;
Gillis, JC .
DRUGS, 1997, 54 (06) :925-975